Aktuellt
SENASTE
Fluoguide announced that its phase 1/2a trial in aggressive glioma was successful, with 100% of patient biopsies illuminated at the high dose of FG001, and only 3/40 patients showing side-effects, all of which were mild, according to the company. As a result, the phase 2b trial will be expanded to 24 patients with aggressive glioma, instead of 12 previously. Fluoguide will run a trial of FG001 in head and neck cancer, an adjacent opportunity not in our model. Positive.
LÄS MER
